Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma. J of Skin. 2018;2:S79. doi:10.25251/skin.2.supp.79